Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.37 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173376 | 0.88 | LTB4R (0.48) | LTB4RPDE4APDE4CPDE4D | |
| SCHEMBL12871206 | 0.85 | LTB4R (0.43) | LTB4RPDE4APDE4CPDE4DCNR2 | |
| SCHEMBL1173587 | 0.79 | BACE1 (0.53) | PDE4APDE4CPDE4D | |
| SCHEMBL8502299 | 0.76 | L3MBTL1 (0.50) | MEN1KMT2APDE4APDE4CPDE4D | |
| SCHEMBL5665844 | 0.74 | ALOX15 (0.50) | KMT2APDE4D | |
| SCHEMBL17480046 | 0.70 | SMN1; SMN2 (0.42) | PDE4APDE4CPDE4D | |
| SCHEMBL244946 | 0.69 | MGAM (0.40) | MEN1KMT2APDE4APDE4CPDE4D | |
| SCHEMBL29461538 | 0.69 | MGAM (0.40) | MEN1KMT2APDE4APDE4CPDE4D | |
| SCHEMBL10049800 | 0.68 | NCF1 (0.45) | — | |
| SCHEMBL15110631 | 0.68 | HTT (0.51) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436173-B2 | Boron compounds, their production processes, and functional electronic devices using same | KYOTO UNIVERSITY (JP) | 2013-05-07 | — | — | US | disclosed |
| US-8436173-B2 | Boron compounds, their production processes, and functional electronic devices using same | KYOTO UNIVERSITY (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110046372-A1 | NOVEL BORON COMPOUNDS, THEIR PRODUCTION PROCESSES, AND FUNCTIONAL ELECTRONIC DEVICES USING SAME | Kyoto University and Nippon Shokubai Co., LTD. | 2011-02-24 | — | — | US | disclosed |
| US-20110046372-A1 | NOVEL BORON COMPOUNDS, THEIR PRODUCTION PROCESSES, AND FUNCTIONAL ELECTRONIC DEVICES USING SAME | Kyoto University and Nippon Shokubai Co., LTD. | 2011-02-24 | — | — | US | disclosed |
| EP-2233490-A1 | NOVEL BORON COMPOUND, METHOD FOR PRODUCING THE SAME, AND FUNCTIONAL ELECTRONIC DEVICE USING THE SAME | Kyoto University (JP) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233490-A1 | NOVEL BORON COMPOUND, METHOD FOR PRODUCING THE SAME, AND FUNCTIONAL ELECTRONIC DEVICE USING THE SAME | Kyoto University (JP) | 2010-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046372-A1 | NOVEL BORON COMPOUNDS, THEIR PRODUCTION PROCESSES, AND FUNCTIONAL ELECTRONIC DEVICES USING SAME | ETFB, SLC40A1, SLC19A1 | LTB4R 1612/4885MEN1 367/4885KMT2A 3637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.